欢迎您加入月均活跃用户100万＋的科研社区！如您有任何系统建议，请；如有合作推广需求，请点此洽谈。
| 近期推荐： | 热 SCI论文AI润色+人工QC服务 | 热 同行专家帮助选刊 | 热 Springer Nature特刊征稿 |
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | BREAST CANCER RESEARCH BREAST CANCER RES （此期刊被最新的JCR期刊SCIE收录） LetPub评分 7.3
51人评分
我要评分
声誉 8.3 影响力 6.6 速度 7.1 | |||||||||||||||||||||
| 期刊ISSN | 1465-5411 | 
蝌蝌APP，让您与同行交流更轻松
 立即下载 | ||||||||||||||||||||
| E-ISSN | 1465-542X | |||||||||||||||||||||
| 2024-2025最新影响因子 （数据来源于搜索引擎） | 5.6 点击查看影响因子趋势图 | |||||||||||||||||||||
| 实时影响因子 | 截止2025年5月19日：5.597 | |||||||||||||||||||||
| 2024-2025自引率 | 1.80%点击查看自引率趋势图 | |||||||||||||||||||||
| 五年影响因子 | 7 | |||||||||||||||||||||
| JCI期刊引文指标 | 1.3 | |||||||||||||||||||||
| h-index | 132 | |||||||||||||||||||||
| CiteScore （ 2025年最新版） |
| |||||||||||||||||||||
| 期刊简介 |
| |||||||||||||||||||||
| 期刊官方网站 | http://breast-cancer-research.biomedcentral.com | |||||||||||||||||||||
期刊投稿格式模板 VIP专享 |
| |||||||||||||||||||||
| 期刊投稿网址 | https://www.editorialmanager.com/brcr/ | |||||||||||||||||||||
| 作者指南网址 | http://breast-cancer-research.biomedcentral.com/submission-guidelines | |||||||||||||||||||||
| 期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足BREAST CANCER RESEARCH的语言要求，还能让BREAST CANCER RESEARCH编辑和审稿人得到更好的审稿体验，让稿件最大限度地被BREAST CANCER RESEARCH编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢 。
提交文稿 | |||||||||||||||||||||
| 是否OA开放访问 | Yes | |||||||||||||||||||||
OA期刊相关信息 | 文章处理费：需要（ GBP2890; USD3990; EUR3290; ） 文章处理费豁免：查看说明 其他费用：没有 期刊主题关键词：oncology、breast cancer 相关链接：Aims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review | |||||||||||||||||||||
| 通讯方式 | BIOMED CENTRAL LTD, 236 GRAYS INN RD, FLOOR 6, LONDON, ENGLAND, WC1X 8HL | |||||||||||||||||||||
| 出版商 | BioMed Central | |||||||||||||||||||||
| 涉及的研究方向 | 医学-肿瘤学 | |||||||||||||||||||||
| 出版国家或地区 | ENGLAND | |||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||
| 出版周期 | Bimonthly | |||||||||||||||||||||
| 出版年份 | 1999 | |||||||||||||||||||||
| 年文章数 | 186点击查看年文章数趋势图 | |||||||||||||||||||||
| Gold OA文章占比 | 100.00% | |||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 97.31% | |||||||||||||||||||||
| WOS期刊SCI分区 （ 2024-2025年最新版） | WOS分区等级：1区
| |||||||||||||||||||||
| 中国科学院《国际期刊预警 名单（试行）》名单 | 2025年03月发布的2025版：不在预警名单中 2024年02月发布的2024版：不在预警名单中 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2020年12月发布的2020版：不在预警名单中 | |||||||||||||||||||||
| 中国科学院SCI期刊分区 （ 2025年3月最新升级版） | 点击查看中国科学院SCI期刊分区趋势图
| |||||||||||||||||||||
| 中国科学院SCI期刊分区 （ 2023年12月升级版） |
| |||||||||||||||||||||
| 中国科学院SCI期刊分区 （ 2022年12月旧的升级版） |
| |||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) Directory of Open Access Journals (DOAJ) | |||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1465-5411%5BISSN%5D | |||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： 12 Weeks | |||||||||||||||||||||
| 平均录用比例 | 网友分享经验： 容易 | |||||||||||||||||||||
| 版面费/APC文章处理费信息 | 文章处理费：需要（ GBP2890; USD3990; EUR3290; ） 文章处理费豁免：查看说明 其他费用：没有 LetPub提供文章处理费（APC）支持服务，可以用人民币支付版面费啦！ | |||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在BREAST CANCER RESEARCH顺利发表。
快看看作者怎么说吧：服务好评 论文致谢 。 提交文稿 | |||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | Retraction: Association of Life's Essential 8 cardiovascular health with breast cancer incidence and mortality according to genetic susceptibility of breast cancer: a prospective cohort study Author: Zhao, Yan; Song, Yang; Li, Xiangmin; Guo, Ayao Journal: BREAST CANCER RESEARCH. 2025; Vol. 27, Issue 1, pp. -. DOI: 10.1186/s13058-025-02021-w PubMed DOI |
| 2. | Machine learning prediction of HER2-low expression in breast cancers based on hematoxylin-eosin-stained slides Author: Du, Jun; Shi, Jun; Sun, Dongdong; Wang, Yifei; Liu, Guanfeng; Chen, Jingru; Wang, Wei; Zhou, Wenchao; Zheng, Yushan; Wu, Haibo Journal: BREAST CANCER RESEARCH. 2025; Vol. 27, Issue 1, pp. -. DOI: 10.1186/s13058-025-01998-8 PubMed DOI |
| 3. | Pharmacovigilance study of adverse reactions of anti-HER-2 drugs for the treatment of HER-2-positive breast cancer based on the FAERS database Author: Han, Jinming; Zhai, Xiaohan; Tao, Xufeng; Li, Yunming; Zhao, Ziqi; Yu, Zhan; Dong, Deshi; Yang, Shilei; Lv, Linlin Journal: BREAST CANCER RESEARCH. 2025; Vol. 27, Issue 1, pp. -. DOI: 10.1186/s13058-025-02013-w PubMed DOI |
| 4. | Phenotypes and cytokines of NK cells in triple-negative breast cancer resistant to checkpoint blockade immunotherapy Author: Wang, Youlong; Jiang, Yongluo; Ding, Fadian; Lu, Jun; Huang, Tong; Zhong, Guanqing; Zhu, Pengfei; Ma, Yue; Li, Jin; Wang, Xinjia; Lin, Jiacai; Zheng, Hongjun; Wang, Weidong; Xu, Yiwei; Lyu, Xiajie; Niu, Yu Si; Qi, Xin; Li, Jinjian; Chen, Bocen; He, Tingting; Zeng, Jiling; Ma, Yifei Journal: BREAST CANCER RESEARCH. 2025; Vol. 27, Issue 1, pp. -. DOI: 10.1186/s13058-025-02003-y PubMed DOI |
| 5. | Early prediction of neoadjuvant therapy response in breast cancer using MRI-based neural networks: data from the ACRIN 6698 trial and a prospective Chinese cohort Author: Du, Siyao; Xie, Wanfang; Gao, Si; Zhao, Ruimeng; Wang, Huidong; Tian, Jie; Liu, Jiangang; Liu, Zhenyu; Zhang, Lina Journal: BREAST CANCER RESEARCH. 2025; Vol. 27, Issue 1, pp. -. DOI: 10.1186/s13058-025-02009-6 PubMed DOI |
| 6. | A ROR1 targeted bispecific T cell engager shows high potency in the pre-clinical model of triple negative breast cancer Author: Wang, Fan; Li, Weina; Han, Guohui; Xie, Jun; Bai, Xiangdong Journal: BREAST CANCER RESEARCH. 2025; Vol. 27, Issue 1, pp. -. DOI: 10.1186/s13058-025-02005-w PubMed DOI |
| 7. | Multimodal recurrence risk prediction model for HR+/HER2-early breast cancer following adjuvant chemo-endocrine therapy: integrating pathology image and clinicalpathological features Author: Wu, Xiaoyan; Li, Yiman; Chen, Jilong; Chen, Jie; Zhang, Wenchuan; Lu, Xunxi; Zhong, Xiaorong; Zhu, Min; Yi, Yuhao; Bu, Hong Journal: BREAST CANCER RESEARCH. 2025; Vol. 27, Issue 1, pp. -. DOI: 10.1186/s13058-025-01968-0 PubMed DOI |
| 8. | Prevalence and concordance of HER2-low and HER2-ultralow status between historical and rescored results in a multicentre study of breast cancer patients in China Author: Lv, Hong; Yue, Junqiu; Zhang, Qingfu; Xu, Fangping; Gao, Peng; Yang, Haifeng; Nie, Xiu; Kong, Lingfei; Zhang, Guanjun; Li, Jianming; Xiao, Shiwei; Wu, Hongmei; Xing, Aiyan; Hong, Min; Fan, Jun; Guan, Huijuan; Cao, Peilong; Ni, Hengli; Yang, Wentao Journal: BREAST CANCER RESEARCH. 2025; Vol. 27, Issue 1, pp. -. DOI: 10.1186/s13058-025-02001-0 PubMed DOI |
| 9. | Clinical efficacy and therapy response prediction of neoadjuvant dalpiciclib plus letrozole in postmenopausal patients with HR+/HER2-stage II-III breast cancer (DARLING 01): a single-arm, open-label, exploratory study Author: Zhang, Lina; Liu, Yueping; Yang, Chao; Ma, Jie; Li, Yuntao; Luo, Ruizhen; Han, Jianjun; Wang, Xiaochun; Zhang, Zhisheng; Ma, Li; Cai, Haifeng; Kong, Xiangshun; Wang, Zunyi; Zhou, Xinping; Shi, Jiajie; Zhang, Yanshou; Wang, Meiqi; Wang, Jiaxing; Geng, Cuizhi Journal: BREAST CANCER RESEARCH. 2025; Vol. 27, Issue 1, pp. -. DOI: 10.1186/s13058-025-01976-0 PubMed DOI |
| 10. | SMYD4 promotes MYH9 ubiquitination through lysine monomethylation modification to inhibit breast cancer progression Author: Yang, Jin-Shuo; Cao, Jun-Ming; Sun, Rui; Zhou, Xue-Jie; Chen, Zhao-Hui; Liu, Bo-Wen; Liu, Xiao-Feng; Yu, Yue; Wang, Xin Journal: BREAST CANCER RESEARCH. 2025; Vol. 27, Issue 1, pp. -. DOI: 10.1186/s13058-025-01973-3 PubMed DOI |
|
|
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2025 中国: LetPub上海 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
增值电信业务经营许可证：沪B2-20211595 网络文化经营许可证：沪网文[2023]2004-152号
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室
安全保密
